Myriad Genetics expands access to MyChoice Test for prostate cancer patients in Japan
Approval by Japan’s MHLW enables use of MyChoice Test as a companion diagnostic for Lynparza in prostate cancer
7 May 2026Product news
Myriad Genetics Inc. has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the use of the MyChoice® Test for prostate cancer patients as a companion diagnostic for Lynparza® (olaparib).
With this regulatory approval in Japan, clinicians can order the Myriad Genetics MyChoice Test to determine homologous recombination deficiency (HRD) status for patients with ovarian cancer, and BRCA1/2 status for patients with breast cancer and prostate cancer, supporting more precise treatment decisions.
Expanded access to precision medicine testing in Japan
“Expanding the MyChoice test into prostate cancer marks an important milestone for Myriad Genetics in Japan,” said Brian Donnelly, Chief Commercial Officer, Myriad Genetics.
“Previously, MyChoice testing was only reimbursed under Japan’s National Health Insurance (NHI) for breast and ovarian cancer patients, so this new approval broadens access to critical genomic insights that help clinicians make informed treatment decisions for their patients. This also reflects Myriad’s continued focus on adding high value precision medicine tests to its Cancer Care Continuum portfolio.”
According to the World Cancer Research Fund, more than 100,000 men are newly diagnosed with prostate cancer annually in Japan, and a portion of those patients will be diagnosed with or later progress to metastatic castration-resistant prostate cancer (mCRPC).
New testing option for castration-resistant prostate cancer
“The reimbursement approval of MyChoice for prostate cancer provides a new testing option for patients with castration-resistant prostate cancer. In addition to the previously available germline BRCA1/2 testing, the inclusion of tumor-based testing is expected to expand the number of patients who may benefit from treatment with PARP inhibitors,” said Dr. Hiroji Uemura, Project Professor, Department of Urological Oncology, Yokohama City University Graduate School of Medicine.
About the MyChoice Test
The MyChoice Test from Myriad Genetics offers comprehensive homologous recombination deficiency (HRD) testing, enabling physicians to identify patients with tumors that have lost the ability to repair double-stranded DNA breaks. This loss of DNA repair capability can result in increased susceptibility to DNA-damaging drugs such as platinum-based chemotherapy or PARP inhibitors, including Lynparza (olaparib).
The MyChoice tests comprise tumor sequencing of the BRCA1 and BRCA2 genes and a composite of three proprietary technologies: loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions. In Japan, the MyChoice Test is offered for breast cancer, ovarian cancer and prostate cancer indications.
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Frequently asked questions
How does the Myriad Genetics MyChoice Test support precision medicine for prostate, breast, and ovarian cancer patients in Japan?
The Myriad Genetics MyChoice Test supports precision medicine in Japan by enabling clinicians to determine homologous recombination deficiency (HRD) status for patients with ovarian cancer and BRCA1/2 status for patients with breast cancer and prostate cancer.
With approval from Japan’s Ministry of Health, Labour and Welfare (MHLW), clinicians can now use the MyChoice Test as a companion diagnostic for Lynparza (olaparib) in prostate cancer, broadening access to genomic insights that help guide more precise treatment decisions.
What is the significance of MHLW approval and NHI reimbursement for the MyChoice Test in Japanese prostate cancer care?
Previously, MyChoice testing was only reimbursed for breast and ovarian cancer patients. The new reimbursement approval for prostate cancer expands access to tumor-based BRCA1/2 and HRD testing for men with castration-resistant and metastatic castration-resistant prostate cancer (mCRPC), potentially increasing the number of patients who may benefit from PARP inhibitor treatments such as Lynparza® (olaparib).
What genomic technologies and biomarkers are included in the Myriad Genetics MyChoice Test for cancer patients in Japan?
The Myriad Genetics MyChoice Test for breast, ovarian, and prostate cancer indications in Japan includes tumor sequencing of the BRCA1 and BRCA2 genes and a composite of three proprietary technologies: loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions. These components provide comprehensive homologous recombination deficiency (HRD) testing, helping physicians identify tumors that have lost the ability to repair double-stranded DNA breaks and may be more susceptible to DNA-damaging therapies such as platinum-based chemotherapy or PARP inhibitors, including Lynparza (olaparib).